Correspondence 0001213900-24-079177 from Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: Sept. 17, 2024 · CIK: 0002022416 · Accession: 0001213900-24-079177
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282017
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Alan Campbell Re: Silexion Therapeutics Corp (the “Company”) Registration Statement on Form S-1 Filed September 10, File No. 333-282017
Dear Mr. Campbell:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-282017) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Eastern Daylight Time, on September 17, 2024 or as soon as possible thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness by email to Gary Emmanuel, Esq., of Greenberg Traurig P.A., at Gary.Emmanuel@gtlaw.com, and to Jonathan M. Nathan, Adv., of Meitar Law Offices, at jonathann@meitar.com. Please also contact either/both of Messrs. Emmanuel or Nathan if you have any other questions or concerns regarding this matter.
[Signature page follows]
Sincerely,
SILEXION THERAPEUTICS CORP
Show Raw Text
CORRESP
1
filename1.htm
Silexion Therapeutics Corp
2 Ha’ma’ayan Street
Modi’in-Maccabim-Reut, Israel 7177871
September 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
Re:
Silexion Therapeutics Corp (the “Company”)
Registration Statement on Form
S-1
Filed September 10,
2024
File No. 333-282017
Dear Mr. Campbell:
Pursuant to Rule 461(a)
under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the effective
date of the Company’s Registration Statement on Form S-1 (File No. 333-282017) be accelerated by the Securities
and Exchange Commission to 4:00 p.m., Eastern Daylight Time, on September 17, 2024 or as soon as possible thereafter. In making this acceleration
request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be
notified of such effectiveness by email to Gary Emmanuel, Esq., of Greenberg Traurig P.A., at Gary.Emmanuel@gtlaw.com, and to Jonathan
M. Nathan, Adv., of Meitar Law Offices, at jonathann@meitar.com. Please also contact either/both of Messrs. Emmanuel or Nathan if you
have any other questions or concerns regarding this matter.
[Signature page follows]
Sincerely,
SILEXION THERAPEUTICS CORP
By:
/s/ Ilan Hadar
Name:
Ilan Hadar
Title:
Chief Executive Officer
cc: Mirit Horenshtein Hadar., Chief Financial Officer, Silexion Therapeutics Corp
Mark Selinger, Esq., Greenberg Traurig P.A.
Gary Emmanuel, Esq., Greenberg Traurig P.A.
J. David Chertok, Adv., Meitar Law Offices
Jonathan M. Nathan, Adv., Meitar Law Offices